4.8 Review

The fibrotic tumor stroma

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 128, Issue 1, Pages 16-25

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI93554

Keywords

-

Funding

  1. NIH [R01 CA105155, R01 HL127283, R01 HL132585, R21 AR060978]
  2. Cancer Prevention Research Institute of Texas Multi-investigator Research [RP120713, RP160652]
  3. Jeane F. Shelby Scholarship Fund
  4. NATIONAL CANCER INSTITUTE [R01CA105155, P50CA070907] Funding Source: NIH RePORTER
  5. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL132585, R01HL127283] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR060978] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Intratumoral fibrosis results from the deposition of a cross-linked collagen matrix by cancer-associated fibroblasts (CAFs). This type of fibrosis has been shown to exert mechanical forces and create a biochemical milieu that, together, shape intratumoral immunity and influence tumor cell metastatic behavior. In this Review, we present recent evidence that CAFs and tumor cells are regulated by provisional matrix molecules, that metastasis results from a change in the type of stromal collagen cross-link, and that fibrosis and inflammation perpetuate each other through proteolytic and chemotactic mediators released into the tumor stroma. We also discuss aspects of the emerging biology that have potential therapeutic value.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available